hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-14 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Osedax antarcticus Glover, Wiklund & Dahlgren, 2013 Osedax bozoi Berman, Hiley, Read & Rouse, 2024 Osedax braziliensis Fujiwara, Jimi, Sumida, Kawato, Kitazato Osedax bryani Rouse, Goffredi, Johnson & Vrijenhoek Osedax byronbayensis Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax craigmcclaini Berman, Hiley, Read, Rouse, 2024 Osedax crouchi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax deceptionensis Taboada, Cristobo, Avila, Wiklund & Glover, 2013 Osedax docricketts Rouse, Goffredi, Johnson & Vrijenhoek Osedax estcourti Berman, Hiley, Read & Rouse, 2024 Osedax fenrisi Eilertsen, Dahlgren & Rapp, 2020 Osedax frankpressi Rouse, Goffredi & Vrijenhoek, 2004 Osedax jabba Rouse, Goffredi, Johnson & Vrijenhoek Osedax japonicus Fujikura, Fujiwara & Kawato, 2006 Osedax knutei Rouse, Goffredi, Johnson & Vrijenhoek Osedax lehmani Rouse, Goffredi, Johnson & Vrijenhoek Osedax lonnyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax mucofloris Glover, Kallstrom, Smith & Dahlgren, 2005 Osedax nataliae Gularte, Sumida, Bergamo & Rouse, 2024 Osedax nordenskjoeldi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax priapus Rouse et al., 2014 Osedax packardorum Rouse, Goffredi, Johnson & Vrijenhoek Osedax randyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax rogersi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax roseus Rouse, Worsaae, Johnson, Jones & Vrijenhoek, 2008 Osedax rubiplumus Rouse, Goffredi & Vrijenhoek, 2004 Osedax ryderi Rouse, Goffredi, Johnson & Vrijenhoek Osedax sigridae Rouse, Goffredi, Johnson & Vrijenhoek Osedax talkovici Rouse, Goffredi, Johnson & Vrijenhoek Osedax tiburon Rouse, Goffredi, Johnson & Vrijenhoek Osedax traceyae Berman, Hiley, Read & Rouse, 2024 Osedax ventana Rouse, Goffredi, Johnson & Vrijenhoek Osedax waadjum Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax westernflyer Rouse, Goffredi, Johnson & Vrijenhoek
The ginkgo leaf is the symbol of the Urasenke school of Japanese tea ceremony. The tree is the official tree of the Japanese capital of Tokyo, and the symbol of Tokyo is a ginkgo leaf. Since 1948, the badge of Tokyo University has been two ginkgo leaves (designed by Shoichi Hoshino), which became the university logo in 2004 with a redesign. The logo of Osaka University has been a simplified ginkgo leaf since 1991 when designer Ikko Tanaka created it for the university's sixtieth anniversary. In professional sumo, wrestlers ranked in the two highest divisions (jūryō and makuuchi) wear an elaborate topknot called ōichōmage (大銀杏髷; lit. 'ginkgo-leaf topknot') because it resembles the leaf of the ginkgo tree. Ginkgo is an official tree of Seoul since 1971, designated by the Seoul Metropolitan Government.
== Indications == The decision to initiate dialysis or hemofiltration in patients with kidney failure depends on several factors. These can be divided into acute or chronic indications. Depression and kidney failure symptoms can be similar to each other. It is important that there is open communication between a dialysis team and the patient. Open communication will allow giving a better quality of life. Knowing the patients' needs will allow the dialysis team to provide more options like: changes in dialysis type like home dialysis for patients to be able to be more active or changes in eating habits to avoid unnecessary waste products.
Sources: en.wikipedia.org
After 1956, 1962, and 1964; East Germany competed in the Summer Olympics as a separate member of the IOC. The 800-page Doping in Germany from 1950 to today study details how the West German government helped fund a wide-scale doping programme. West Germany encouraged and covered up a culture of doping across many sports for decades. As in 1957, when the Saarland acceded, East German sport organisations ceased to exist in late 1990 as their subdivisions and their members joined their Western counterparts. Thus, the present German organisations and teams in football, Olympics and elsewhere are identical to those that had been informally called "West German" before 1991. The only differences were a larger membership and a different name used by some foreigners. These organisations and teams in turn mostly continued the traditions of those that represented Germany before the Second World War, and even the First World War, thus providing a century-old continuity despite political changes. On the other hand, the separate East German teams and organisations were founded in the 1950s; they were an episode lasting less than four decades, yet quite successful in that time. West Germany played 43 matches at the European Championships, more than any other national team.
==== MeSH D12.776.964.775.375 – gene products, pol (gene) ==== MeSH D12.776.964.775.375.325 – fusion proteins, gag-pol MeSH D12.776.964.775.375.335 – hiv integrase MeSH D12.776.964.775.375.340 – HIV protease MeSH D12.776.964.775.375.750 – RNA-directed DNA polymerase MeSH D12.776.964.775.375.750.375 – hiv-1 reverse transcriptase
== Stimulants == Stimulants produce a variety of different kinds of effects by enhancing the activity of the central and peripheral nervous systems. Common effects, which vary depending on the substance and dosage in question, may include enhanced alertness, awareness, wakefulness, endurance, productivity, and motivation, increased arousal, locomotion, heart rate, and blood pressure, and the perception of a diminished requirement for food and sleep.
The presence of breast implants currently presents no contraindication to breast feeding, and there is no evidence to support that the practice may present health issues to a breastfeeding infant. Women with breast implants may have functional breast-feeding difficulties; mammoplasty procedures that feature periareolar incisions are especially likely to cause breastfeeding difficulties. Surgery may also damage the lactiferous ducts and the nerves in the nipple-areola area. Functional breastfeeding difficulties arise if the surgeon cut the milk ducts or the major nerves innervating the breast, or if the milk glands were otherwise damaged. Milk duct and nerve damage are more common if the incisions cut tissue near the nipple. The milk glands are most likely to be affected by subglandular implants and by large-sized breast implants, which pinch the lactiferous ducts and impede milk flow. Small-sized breast implants and submuscular implantation cause fewer breast-function problems; however, it is impossible to predict whether a woman who undergoes breast augmentation will be able to successfully breast feed since some women are able to breast-feed after periareolar incisions and subglandular placement and some are not able to after augmentation using submuscular and other types of surgical incisions.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.